학술논문
Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes
Document Type
Article
Author
Source
In: Cancers . (Cancers, October 2023, 15(19))
Subject
Language
English
ISSN
20726694